OrbiMed’s Ocular Therapeutix OCUL Stock Holding History

OrbiMed’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-157,300	Closed	-$1.91M	–	123
2025 Q4	$1.91M	Buy	+157,300	New	+$1.91M	0.04%	101
2016 Q1	–	Sell	-155,000	Closed	-$1.45M	–	144
2015 Q4	$1.45M	Sell	155,000 -53,900	-26%	-$582K	0.01%	119
2015 Q3	$2.94M	Buy	+208,900	New	+$4.2M	0.03%	121

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

OrbiMed's OCUL Position: Q1 2026 in Review

OrbiMed sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 157,300 shares — an estimated $1.91M sold.

OrbiMed first reported a position in OCUL in Q3 2015 and held it in 3 quarters. The position peaked at $2.94M in Q3 2015. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

OrbiMed reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
OrbiMed sold 157,300 Ocular Therapeutix shares in Q1 2026, an estimated $1.91M.
OrbiMed first reported a position in Ocular Therapeutix in Q3 2015 and held it in 3 quarters.
OrbiMed's Ocular Therapeutix position peaked at $2.94M in Q3 2015.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.